Citing “family health reasons,” Johnson & Johnson’s Alex Gorsky will hand the CEO role over to Joaquin Duato, current vice-chair of the company’s executive committee, at the start of the new year.
Gorsky oversaw a near-decade of significant growth at the medtech and pharma giant. His tenure ultimately will be capped off by Johnson & Johnson’s development of a single-shot vaccine for COVID-19, an alternative to the dominant two-shot mRNA-based vaccines.
Get the full story on our sister site MassDevice.
Filed Under: Drug Discovery and Development
